Clinical observation of patients with hematologic malignancies treated with hematopoietic stem cell transplantation

Abstract

To evaluate the therapeutic effect of hematopoietic stem cell transplantation (HSCT), we performed HSCT in 30 patients with hematologic maligancies. Of the 30 patients, 10 underwent autologous peripheral blood stem cell transplantation (auto-PBSCT), 13 underwent myeloablative allogeneic HSCT while 7 underwent nonmyeloablative allogeneic HSCT, which were designated as autologous group, myeloablative group and nonmyeloablative group, respectively. All patients except the one who underwent cord blood transplantation, were successfully engrafted. Median time for the granulocytes≥0.5×10⁵/L and platelets≥20×10⁹/L were 12 days and 13 days respectively in autologous group, 16 days and 19 days in myeloablative group, 15 days and 12 days in nonmyeloablative group. In myeloablative group, acute graft-versus-host discases (aGVHD) was observed in 3 patients, all of which were I–II grade. Oral mucous cGVHD was observed in 1 patient. In nonmyeloablative group, 1 patient developed intestinal aGVHD grade IV and cutaneous cGVHD was induced by donor lymphocyte infusions (DLI) in 3 patients, 1 patient had hematological relapse in autologous group, 1 patient had cytogenetic relapse in myeloablative group. In nonmyeloablative group 3 patients had cytogenetic relapse and were cured by DLI, 1 patient had hematological relapse, 4 of the 30 patients died of infection (2 patients), grade IV aGVHD (1) and relapse (1) respectively, 26 patients are still alive. 3 years overall survival (OS) and 3 years disease free survival (DFS) were 100% and 64.81% respectively in autologous group, 78.75% and 63% respectively in myeloablative group while both 66. 67% in nonmycloablative group. In conclusion, autologous group had less transplant-related complications and mortality. Active prophylaxis of relapse could significantly promote DFS. The transplant-related mortality limited DFS in myeloablative group. More relapses occurred in nonmyeloablative group, but could be cured by DLI.

Keywords

hematopoietic stem cell transplantation / leukemia / lymphoma / disease free survival

References

[1] ShigeyoshiI. Cryopreservation of peripheral blood stem cells. J Clin Exper Med, 1996, 176579-579

[2] ZhangD H, RanD, XiaoY, et al. . The clinical observation of depleting effectively ABO-incompatible red blood cells of donors of HSCT by using succiny-gelatin solution for injection (Chinese). Chin J Hematol, 2004, 25106-106

[3] ZhangZ N, ShenT. Diagnosis and Treatment Criteria for Hematological Diseases (Chinese), 19982nd edBeijing, Publishing House of Science and Technology: 215-215

[4] RubiaJ, SanzM A. Autologous peripheral blood stem cell transplantation for acute leukaemias. Baillière’s Clin Haematol, 1999, 12139-139

[5] CoubanS, SimpsonD R, BarnettM J, et al. . A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood, 2002, 1001525-1525

[6] RingdénO, LabopinM, GorinNC, et al. . Treatment With Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation for Acute Leukemia Increases the Risk of Graft-Versus-Host Disease and Death: A Study From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol, 2004, 22416-416

[7] HanZ C. The Theory and Techniques of of Transplantation of Hematopoietic Stem Cells (Chinese), 2000, Zhenzhou, Henan Publishing House of Sciences and Technologies: 143-143

[8] BertzH, AftingM, KreiselW, et al. . Feasibility and response to budesonide as topieal corticosteroid therapy for acute intestinal GVHD. J Bone Marrow Transplant, 1999, 24(11): 1185-1185

[9] MohtyM, KuentzM, MichalletM, et al. . Chronic graftversus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood, 2002, 1003128-3128

[10] CarellalA M, ChamplinR, SlavinS, et al. . Mini-allografts: ongoing trials in humans. Bone Marrow Transplant, 2000, 25345-345